David Solomon, CEO of Pharnext 00:00:00
David Solomon, CEO of Pharnext, a Euronext Paris-listed company developing medicines for neurological disorders based on its Pleotherapy platform, which unearths new therapeutic effects from drug combinations. Its lead program is PXT3003 for Charcot-Marie-Tooth disease